Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Is it this week ?

<< Previous

Bullboard Posts

Next >>

Comment by Genie29jon Aug 29, 2023 8:45pm

77 Views

Post# 35611031

RE:RE:RE:RE:Is it this week ?

As I read your message below, the sad reality is all these desires for the AGM are copy / paste from 2022, 2021, 2020, 2029, etc.

you get the picture.

Nothing has changed. Nothing will change until they get a deal done for RCH-01.

if there's no deal, I can't help but wonder if this is the last AGM meeting, essentially saying goodbye

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market